Department of Biomedical Sciences for Health, 9304University of Milan, Milan, Italy.
Gastroenterology Unit, Avellino Hospital, Avellino, Italy.
J Int Med Res. 2021 Jan;49(1):300060520982657. doi: 10.1177/0300060520982657.
Postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS) are the two main forms of functional dyspepsia (FD). Probiotics are a promising therapy for FD, but current data remains heterogeneous. This work aims to evaluate a probiotic combination of LR04 (DSM 16605), LPS01 (DSM 21980), LP01 (LMG P-21021), and subsp. LDD01 (DMS 22106), alone or together with other pharmacological therapies, for clinical improvement of symptoms associated with FD.
Patients with FD were enrolled and divided into two groups: PDS and EPS. Probiotic alone or combined with prokinetics, antacids, or proton-pump-inhibitors were administered for 30 days. A progressive-score scale was used to evaluate symptoms in all patients at the beginning of the trial and at 15 days after the end of treatment.
A cohort of 2676 patients were enrolled (1 357 with PDS; 1 319 with EPS). All patients showed significant improvements in dyspeptic symptoms following treatment. In patients with PDS, probiotic alone resulted in the lowest prevalence of symptoms following treatment, while patients with EPS showed no clear between-treatment differences.
Dyspeptic symptoms were reduced following treatment in all patients.
餐后不适综合征（PDS）和上腹疼痛综合征（EPS）是功能性消化不良（FD）的两种主要形式。益生菌是治疗 FD 的一种很有前途的方法，但目前的数据仍然存在异质性。本研究旨在评估 LR04（DSM 16605）、LPS01（DSM 21980）、LP01（LMG P-21021）和 subsp. LDD01（DMS 22106）四种益生菌组合单独或与其他药物治疗联合应用，对 FD 相关症状的临床改善作用。
纳入 FD 患者，并分为 PDS 和 EPS 两组。单独使用益生菌或联合使用促动力药、抗酸药或质子泵抑制剂治疗 30 天。在试验开始时和治疗结束后 15 天，所有患者均使用渐进评分量表评估症状。
共纳入 2676 例患者（PDS 患者 1357 例，EPS 患者 1319 例）。所有患者的消化不良症状在治疗后均有显著改善。在 PDS 患者中，单独使用益生菌治疗后症状的发生率最低，而 EPS 患者之间的治疗差异不明显。
所有患者的消化不良症状在治疗后均有所减轻。
